Hormonal
Increased levels of coagulation factors (specifically Factor Xa) and the resulting activation of protease-activated receptors (PAR-1/2) contribute to chronic inflammation and cell senescence through the IGFBP-5 pathway.
Coagulation factors like Factor Xa can promote inflammation and cell senescence through specific signaling pathways. This links blood clotting mechanisms to chronic inflammation and aging-related diseases. While not a direct lifestyle intervention, understanding this link highlights the importance of cardiovascular health in managing inflammation.
Activation of the coagulation cascade following fibrinogen activation may increase thrombosis, and elevated levels of coagulation factor Xa and thrombin could enhance the inflammatory response through PAR-1/2, in addition to its roles in coagulation and the fibrinolysis system.
Why this rating
Based on mechanistic studies, animal models, and clinical trial data (ATLAS ACS 2-TIMI 51) linking coagulation factors to cardiovascular outcomes and inflammation.
Source
Source of Chronic Inflammation in Aging
Fumihiro Sanada et al. · Frontiers in Cardiovascular Medicine · 2018
DOI 10.3389/fcvm.2018.00012
More from this paper
- Cellular senescence and the resulting Senescence-Associated Secretory Phenotype (SASP) are primary drivers of chronic low-grade inflammation (inflammaging) in aging, contributing to age-related diseases such as atherosclerosis, cancer, and diabetes.Moderate
- Dysregulation of the gut microbiota (dysbiosis) in the elderly, characterized by decreased diversity and reduced anti-inflammatory bacteria, is a source of chronic low-grade inflammation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →